REGN Q3 2023 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.4B+14.5% YoY

Gross Profit

$2.8B83.9% margin

Operating Income

$1.2B36.0% margin

Net Income

$1.0B30.0% margin

EPS (Diluted)

$8.89

QoQ Revenue Growth

+6.5%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$938M

Stock-Based Comp.

$204M

Balance Sheet

Total Assets

$32.2B

Total Liabilities

$7.3B

Stockholders' Equity

$24.9B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.4B	$2.9B	+14.5%
Gross Profit	$2.8B	$2.5B	+11.7%
Operating Income	$1.2B	$1.2B	-1.0%
Net Income	$1.0B	$1.3B	-23.4%

Revenue Segments

Product

$1.8B53%

Collaboration Revenue

$1.4B43%

Product and Service, Other

$138M4%